You are here: Industry Insights > sma

News List

Novartis Receives Approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma americanpharmaceuticalreview
March 23, 2020
Novartis Pharma announced the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Zolgensma® (onasemnogene abeparvovec).
Novartis gets Japan’s approval for Zolgensma pharmaceutical-technology
March 20, 2020
Novartis Pharma has received the Japanese Ministry of Health, Labour and Welfare (MHLW) approval for Zolgensma (onasemnogene abeparvovec) to treat spinal muscular atrophy (SMA).
History of the “Sky-high Priced” Imported Drug to China: Nusinersen Injection PharmaSources/zhulikou431
November 14, 2019
Nusinersen Injection, the world’s first SMA (Spinal Muscular Atrophy) precision targeted therapy, was completed the intrathecal injection to the first SMA patients in China on Oct. 10, 2019, marking a new milestone of SMA treatment.
Biogen and Invitae to Offer Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients americanpharmaceuticalreview
August 21, 2019
Biogen Inc. and Invitae Corporation have announced that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy (SMA), will be offered at no charge to individuals in the U.S. as part of the SMA Identified program.
AveXis’ Zolgensma Aproved for Pediatric Patients with Spinal Muscular Atrophy contractpharma
June 14, 2019
The first and only gene therapy approved by the FDA for the treatment of SMA, including those who are pre-symptomatic at diagnosis.
Zolgensma: First Gene Therapy for Pediatric Spinal Muscular Atrophy (SMA) drugs
June 03, 2019
First Gene Therapy for Pediatric Spinal Muscular Atrophy (SMA).
FDA Approves First Gene Therapy Zolgensma (Onasemnogene Abeparvovec-xioi) for Spinal Muscular Atrophy drugs
May 29, 2019
FDA Approves First Gene Therapy Zolgensma (Onasemnogene Abeparvovec-xioi) for Spinal Muscular Atrophy.
Zolgensma wins FDA green light in child SMA pharmatimes
May 28, 2019
The U.S. Food and Drug Administration (FDA) has approved Novartis’ Zolgensma (onasemnogene abeparvovec-xioi) at a cost of $2.1 milllion per treatment.
Biogen’s SMA drug Spinraza to be available on NHS pharmaceutical-technology
May 22, 2019
The UK’s National Health Service (NHS) has signed a managed access agreement to fund Biogen’s antisense oligonucleotide (ASO) Spinraza (nusinersen) for a limited time to ascertain its effectiveness as a treatment for 5q spinal muscular atrophy (SMA).
NHS England agree to pay for Biogen's $750,000 a year SMA treatment Spinraza pharmafile
May 16, 2019
NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza.

Previous page 1 2 3 4 5 6 Next page